NightBalance acquired by Royal Philips - Gilde Healthcare

NightBalance acquired by Royal Philips

7 mei 2018

Utrecht, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has acquired NightBalance, a portfolio company from specialist investor Gilde Healthcare. Netherlands-based NightBalance is a digital health scale-up company commercializing an innovative, easy to use device to treat positional obstructive sleep apnea and positional snoring. With the acquisition of NightBalance, Philips expands its Sleep & Respiratory Care portfolio. Financial details of the transaction were not disclosed.

NightBalance’s Sleep Position Trainer (SPT) was designed as a patient friendly treatment alternative for people who suffer from positional obstructive sleep apnea. The SPT gently prompts them not to sleep on their back, avoiding the apneas from occurring during sleep. The SPT is CE-marked and is currently marketed in select countries in Europe. The acquisition will help Philips to further expand its leadership position in the growing home care market, and its ability to deliver integrated solutions that drive efficiencies and improved outcomes. Philips already offers a broad range of care solutions for people living with obstructive sleep apnea.

 

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in digital health, medtech and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Benelux and DACH-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market.
For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare company Shoulder Innovations Announces Pricing of Initial Public Offering

Shoulder Innovations, Inc. (“Shoulder Innovations”), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock...
31 juli 2025

Gilde Healthcare company PureSpring announces FDA IND clearance for Phase 1/2 trial for primary IgA nephropathy (IgAN)

Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney diseases, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PS-002, enabling...
9 juli 2025

Gilde Healthcare’s private equity fonds bundelt Artinis en NIRx tot wereldleider in neuro-imaging

Gilde Healthcare kondigt vandaag de gecombineerde private equity investering aan in Artinis Medical Systems (Nederland) en NIRx Medical Technologies (Duitsland/Verenigde Staten), beiden pioniers op het gebied van functionele Near-Infrared Spectroscopy (fNIRS). Door deze dubbele transactie...
8 juli 2025